Business Description
Aligos Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US01626L1052
Share Class Description:
ALGS: Ordinary SharesDescription
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.18 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.73 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 48.1 | |||||
| 3-Year EPS without NRI Growth Rate | 50 | |||||
| 3-Year FCF Growth Rate | 45.6 | |||||
| 3-Year Book Growth Rate | -41.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.26 | |||||
| 9-Day RSI | 33.85 | |||||
| 14-Day RSI | 38.25 | |||||
| 6-1 Month Momentum % | 59.38 | |||||
| 12-1 Month Momentum % | -1.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | |||||
| Quick Ratio | 5.9 | |||||
| Cash Ratio | 5.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.1 | |||||
| Shareholder Yield % | 2.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -567.5 | |||||
| Net Margin % | -564.62 | |||||
| FCF Margin % | -508.75 | |||||
| ROE % | -108.2 | |||||
| ROA % | -71.64 | |||||
| ROIC % | -350.45 | |||||
| ROC (Joel Greenblatt) % | -788.85 | |||||
| ROCE % | -92.35 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.36 | |||||
| PB Ratio | 0.64 | |||||
| Price-to-Tangible-Book | 0.64 | |||||
| EV-to-EBIT | 0.71 | |||||
| EV-to-EBITDA | 0.74 | |||||
| EV-to-Revenue | -4.04 | |||||
| EV-to-FCF | 0.79 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.77 | |||||
| Earnings Yield (Greenblatt) % | 140.85 | |||||
| FCF Yield % | -133.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALGS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aligos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 15.529 | ||
| EPS (TTM) ($) | -1.741 | ||
| Beta | 2.26 | ||
| Volatility % | 66.53 | ||
| 14-Day RSI | 38.25 | ||
| 14-Day ATR ($) | 0.078444 | ||
| 20-Day SMA ($) | 0.914765 | ||
| 12-1 Month Momentum % | -1.45 | ||
| 52-Week Range ($) | 0.5388 - 1.38 | ||
| Shares Outstanding (Mil) | 75.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aligos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aligos Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aligos Therapeutics Inc Frequently Asked Questions
What is Aligos Therapeutics Inc(ALGS)'s stock price today?
The current price of ALGS is $0.78. The 52 week high of ALGS is $1.38 and 52 week low is $0.54.
When is next earnings date of Aligos Therapeutics Inc(ALGS)?
The next earnings date of Aligos Therapeutics Inc(ALGS) is 2024-05-03 Est..
Does Aligos Therapeutics Inc(ALGS) pay dividends? If so, how much?
Aligos Therapeutics Inc(ALGS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers